The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Outcome and dose intensity (DI) in the elderly subgroup of the AGITG MAX phase III trial of capecitabine (C), bevacizumab (B), and mitomycin C (M) in first-line metastatic colorectal cancer (CRC).
T. J. Price
Consultant or Advisory Role - Roche (U)
D. Zannino
No relevant relationships to disclose
K. Wilson
No relevant relationships to disclose
J. Simes
No relevant relationships to disclose
G. A. Van Hazel
Consultant or Advisory Role - Roche
B. A. Robinson
No relevant relationships to disclose
A. Broad
No relevant relationships to disclose
V. Ganju
No relevant relationships to disclose
S. P. Ackland
No relevant relationships to disclose
N. C. Tebbutt
Consultant or Advisory Role - Roche (U)